Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
0.8010
-0.0060 (-0.74%)
Apr 2, 2026, 4:00 PM EDT - Market closed
Immuron Employees
Immuron had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$712,477
Profits / Employee
-$442,735
Market Cap
6.27M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 7 | 0 | - |
| Jun 30, 2024 | 7 | 1 | 16.67% |
| Jun 30, 2023 | 6 | 1 | 20.00% |
| Jun 30, 2022 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioRestorative Therapies | 11 |
| XTL Biopharmaceuticals | 10 |
| Purple Biotech | 10 |
| MetaVia | 9 |
| Artelo Biosciences | 7 |
| Addex Therapeutics | 2 |
| Xenetic Biosciences | 2 |
| Alaunos Therapeutics | 1 |
IMRN News
- 4 weeks ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.90 Price Target - Accesswire
- 4 weeks ago - Immuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference - Benzinga
- 2 months ago - Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target - Accesswire
- 2 months ago - Immuron Reports Continued Sales Growth - GlobeNewsWire
- 4 months ago - Immuron (IMRN) Collaborates on Vaccine Research with US Military Institutes - GuruFocus
- 5 months ago - Immuron (IMRN) Secures FDA Approval for Phase 2 Trial of IMM-529 - GuruFocus
- 5 months ago - Immuron: FDA Approves IND Application For IMM-529 - Nasdaq
- 5 months ago - Immuron IMM-529 IND approved by FDA - GlobeNewsWire